Metformin on the Presence of COVID-19 Symptoms 6 Months after Infection: The ACTIV-6 Randomized Clinical Trial - PubMed
3 hours ago
- #Long COVID
- #Metformin
- #Randomized Trial
- The ACTIV-6 trial was a quadruple-blinded, randomized, placebo-controlled study evaluating metformin for treating acute COVID-19 in low-risk adults to prevent long COVID symptoms.
- Participants (n=2983) were adults ≥30 years old with confirmed SARS-CoV-2 infection and ≥2 symptoms, enrolled within 7 days of symptom onset; most had prior immunity (83% with prior infection or vaccination).
- Metformin was administered for 14 days; primary outcome was PASCD (post-acute sequelae), assessed by self-reported symptoms attributed to COVID-19 at day 180, while a secondary outcome was clinician-diagnosed long COVID.
- At day 180, 2.6% of participants reported COVID-19 symptoms; metformin showed a 0.8 percentage point reduction in risk of symptoms (95% CrI -2.2 to 0.6), failing to exceed the preset efficacy threshold.
- Metformin reduced the risk of clinician-diagnosed long COVID by 0.7 percentage points (95% CrI -1.5 to 0.1) and had a risk ratio of 0.495, with a posterior probability of efficacy of 0.96 for this outcome.